^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Pancreatic Cancer
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

    Excerpt:
    ...Known mutation status of KRAS and BRAF kinases....
    Trial ID:
    NCT05068752
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nat Commun
    Title:

    Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

    Excerpt:
    Oncogenic BRAF mutations are mutually exclusive with KRAS and define sensitivity to vemurafenib in PDA models.
    DOI:
    10.1038/ncomms7744